Business Context and Reporting Period
Company: Halozyme Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Filing Date: August 10, 2006
Reporting Period: The filing announces the issuance of a press release reporting financial results for the three and six months ended June 30, 2006.
Key Financial Metrics
The provided text serves as a cover report referencing an attached press release (Exhibit 99.1). The filing text itself does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. Specific financial figures are contained within the referenced press release, which is not included in the input text.
Material Changes
No material changes or comparative financial data are detailed in the filing text. The document solely confirms the release of results for the periods ended June 30, 2006.
Guidance, Outlook, and Risks
Management Commentary: The filing notes that the press release is furnished under Item 2.02 but explicitly states it shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor subject to the liabilities of that section.
Risks and Contingencies: No specific risks, contingencies, or unusual items are described in the text of this 8-K.
Investor Verification Checklist
- Review the attached Exhibit 99.1 (Press Release dated August 10, 2006) for actual revenue, net loss, and cash position figures.
- Verify the specific financial performance for the three and six months ended June 30, 2006, as these are not listed in the 8-K body.
- Confirm the status of the press release regarding legal liability under Section 18 of the Exchange Act as noted in the filing.